Form 4: RAPT Therapeutics Director Mary Ann Gray Granted Significant Stock Options

RAPT Therapeutics, Inc. Director Mary Ann Gray was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.

Summary

• Mary Ann Gray, a Director of RAPT Therapeutics, Inc. (RAPT), was granted 257,832 Director Stock Options on May 29, 2025.
• Each option has an exercise price of $0.93.
• The options will vest in 12 equal monthly installments starting from the grant date of May 29, 2025.
• The options expire on May 28, 2035.
• Following this transaction, Ms. Gray beneficially owns 257,832 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders and is a standard form of compensation, indicating continued commitment to the company's long-term success.

Positives

• The grant of 257,832 stock options to Director Mary Ann Gray aligns her interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $0.93 per share is relatively low, suggesting potential for future upside if the stock price increases.

Future Outlook

The stock options granted to Director Mary Ann Gray will vest in 12 equal monthly installments from May 29, 2025, indicating a future commitment period for the director's equity incentive and aligning her compensation with future company performance.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align their interests with long-term shareholder value creation and retain talent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism, comparable to practices at other small to mid-cap biotechnology companies.
• The specific size of the grant (257,832 options) and the exercise price ($0.93) would typically be evaluated against peer group compensation data and the company's own compensation philosophy, though such detailed comparative data is not provided in this filing.

Related Party Transactions

• The grant of stock options to Mary Ann Gray, a Director of RAPT Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider. This is a standard and disclosed practice for director remuneration.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially incentivizing decisions that enhance long-term stock value and performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The granted stock options will vest in 12 equal monthly installments from May 29, 2025, with the first vesting occurring approximately one month after the grant date.

Key Dates

Keywords

RAPT Therapeutics, RAPT, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership